Product Information
MYDAYIS ER 12.5 MG CAPSULE is a brand product labeled by Takeda Pharmaceuticals America, Inc., priced at $10.7593 per EA under NDC 54092046801. Its NADAC has been published 453 times since Dec 20, 2017.
FDA first approved this application on Jun 20, 2017. Its Orange Book therapeutic-equivalence code is AB2 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
MYDAYIS ER 12.5 MG CAPSULE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, and AMPHETAMINE SULFATEStrength
3.125; 3.125; 3.125; 3.125 mg/1; mg/1; mg/1; mg/1
Manufacturer
Takeda Pharmaceuticals America, Inc.NDC
54092046801
Classification
Brand
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
AMPHETAMINE ASPARTATE MONOHYDRATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATEApproval Type
New Drug (NDA)
FDA Application
NDA022063FDA Approved
6/20/2017
TE Code
AB2
On Market Since
6/20/2017
Pharmacological Classes
Price Statistics
The NADAC for MYDAYIS ER 12.5 MG CAPSULE has been published 453 times since Dec 20, 2017, and over the history we have for it it has risen 24.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $10.7593 per EA |
|---|---|
| All-time high | $10.8668 (Oct 11, 2023) |
| All-time low | $8.6160 (Sep 19, 2018) |
| 52-week high | $10.8394 |
| 52-week low | $10.7516 |
| Median price | $10.3493 |
| Average price | $9.9987 |
| Largest weekly change | +5.0% (Jan 29, 2020) |
| Weeks tracked | 453 |
| Tracking since | Dec 20, 2017 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, and AMPHETAMINE SULFATE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of MYDAYIS ER 12.5 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for MYDAYIS ER 12.5 MG CAPSULE, manufactured by Takeda Pharmaceuticals America, Inc., is $10.7593 per EA (NDC 54092046801), effective Aug 19, 2026.
How has the price of MYDAYIS ER 12.5 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for MYDAYIS ER 12.5 MG CAPSULE has risen 24.9%. It has been tracked across 453 weekly CMS publications since Dec 20, 2017.
What are the highest and lowest recorded NADAC prices for MYDAYIS ER 12.5 MG CAPSULE?
Since Dec 20, 2017, the NADAC for MYDAYIS ER 12.5 MG CAPSULE has ranged from a low of $8.6160 (Sep 19, 2018) to a high of $10.8668 (Oct 11, 2023), with a median of $10.3493 per EA.
Are there cheaper alternatives to MYDAYIS ER 12.5 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of MYDAYIS ER 12.5 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures MYDAYIS ER 12.5 MG CAPSULE?
MYDAYIS ER 12.5 MG CAPSULE (NDC 54092046801) is labeled by Takeda Pharmaceuticals America, Inc., and CMS classifies it as a brand product.